Inovio Pharmaceuticals(US:INO) Prnewswire·2026-02-11 14:22Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status set for April 7, 2026 [1] Group 1: Allegations Against Inovio Pharmaceuticals - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device [1] - It is claimed that Inovio is unlikely to submit the Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024 due to these deficiencies [1] - The company reportedly lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [1] Group 2: Impact on Stock Price - Following the FDA's announcement that it accepted Inovio's BLA for INO-3107 on a standard review timeline, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [1] Group 3: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1]